These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7573578)

  • 21. Fluorodeoxyglucose brain metabolism studied by NMR and PET.
    Bolo NR; Brennan KM; Jones RM; Budinger TF
    Ann N Y Acad Sci; 1987; 508():451-9. PubMed ID: 3501936
    [No Abstract]   [Full Text] [Related]  

  • 22. PET with fluorine-18 deoxyglucose for pancreatic disease.
    Klever P; Bares R; Fass J; Büll U; Schumpelick V
    Lancet; 1992 Nov; 340(8828):1158-9. PubMed ID: 1359226
    [No Abstract]   [Full Text] [Related]  

  • 23. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose.
    Levivier M; Goldman S; Pirotte B; Brucher JM; Balériaux D; Luxen A; Hildebrand J; Brotchi J
    J Neurosurg; 1995 Mar; 82(3):445-52. PubMed ID: 7861223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET cancer evaluations with FDG.
    Hawkins RA; Hoh C; Dahlbom M; Choi Y; Glaspy J; Tse N; Slamon D; Chen B; Messa C; Maddahi J
    J Nucl Med; 1991 Aug; 32(8):1555-8. PubMed ID: 1869978
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of ethanol, diazepam and amphetamines on cerebral metabolic rate: PET studies using FDG.
    de Wit H; Metz J; Cooper M
    NIDA Res Monogr; 1990; 105():61-7. PubMed ID: 1876142
    [No Abstract]   [Full Text] [Related]  

  • 26. Functional brain imaging in 200 patients after whiplash injury.
    Otte A; Mueller-Brand J; Nitzsche EU; Wachter K; Ettlin TM
    J Nucl Med; 1997 Jun; 38(6):1002. PubMed ID: 9189162
    [No Abstract]   [Full Text] [Related]  

  • 27. Preclinical stages in subjects at risk for neurological disorders: can PET-FDG tell us more?
    Azari NP; Pietrini P
    J Neurol; 1995 Jan; 242(2):112-4. PubMed ID: 7707087
    [No Abstract]   [Full Text] [Related]  

  • 28. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
    Brock CS; Meikle SR; Price P
    Eur J Nucl Med; 1997 Jun; 24(6):691-705. PubMed ID: 9169580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose.
    Wahl RL; Cody R; Hutchins G; Mudgett E
    N Engl J Med; 1991 Jan; 324(3):200. PubMed ID: 1984203
    [No Abstract]   [Full Text] [Related]  

  • 30. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate.
    Kuwabara H; Gjedde A
    J Nucl Med; 1991 Apr; 32(4):692-8. PubMed ID: 2013809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac clinical utility of fluorinated deoxyglucose.
    Bianco JA
    J Nucl Med; 1991 May; 32(5):892-4. PubMed ID: 2023004
    [No Abstract]   [Full Text] [Related]  

  • 32. [Localized imaging with 18F-fluorodeoxyglucose].
    Paul R; Ahonen A
    Duodecim; 1985; 101(12):1167-77. PubMed ID: 3874764
    [No Abstract]   [Full Text] [Related]  

  • 33. Emission computed tomography in the study of human epilepsy.
    Kuhl DE; Engel J; Phelps ME
    Res Publ Assoc Res Nerv Ment Dis; 1983; 61():327-40. PubMed ID: 6601815
    [No Abstract]   [Full Text] [Related]  

  • 34. PET quantitation: blessing and curse.
    Di Chiro G; Brooks RA
    J Nucl Med; 1988 Sep; 29(9):1603-4. PubMed ID: 3261788
    [No Abstract]   [Full Text] [Related]  

  • 35. Functional brain imaging in HIV-1-infected children born to seropositive mothers.
    Depas G; Chiron C; Tardieu M; Nuttin C; Blanche S; Raynaud C; Syrota A
    J Nucl Med; 1995 Dec; 36(12):2169-74. PubMed ID: 8523099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
    Rigo P; Paulus P; Kaschten BJ; Hustinx R; Bury T; Jerusalem G; Benoit T; Foidart-Willems J
    Eur J Nucl Med; 1996 Dec; 23(12):1641-74. PubMed ID: 8929320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?
    Alavi A; Buchpiguel CA; Loessner A
    J Nucl Med; 1994 Oct; 35(10):1650-2. PubMed ID: 7931665
    [No Abstract]   [Full Text] [Related]  

  • 38. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
    Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC
    Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission tomography.
    Cohen RM; Semple WE; Gross M
    Psychiatr Clin North Am; 1986 Mar; 9(1):63-79. PubMed ID: 3515332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain.
    Buchpiguel CA; Alavi JB; Alavi A; Kenyon LC
    J Nucl Med; 1995 Jan; 36(1):159-64. PubMed ID: 7799071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.